These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 28232049)

  • 21. Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
    Dittmar RL; Liu S; Tai MC; Rajapakshe K; Huang Y; Longton G; DeCapite C; Hurd MW; Paris PL; Kirkwood KS; Coarfa C; Maitra A; Brand RE; Killary AM; Sen S
    Cancer Prev Res (Phila); 2021 Jul; 14(7):729-740. PubMed ID: 33893071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exosomal miRNA Biomarker Panel for Pancreatic Ductal Adenocarcinoma Detection in Patient Plasma: A Pilot Study.
    Makler A; Asghar W
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
    Balasenthil S; Huang Y; Liu S; Marsh T; Chen J; Stass SA; KuKuruga D; Brand R; Chen N; Frazier ML; Jack Lee J; Srivastava S; Sen S; McNeill Killary A
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
    Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
    Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
    Nakamura K; Zhu Z; Roy S; Jun E; Han H; Munoz RM; Nishiwada S; Sharma G; Cridebring D; Zenhausern F; Kim S; Roe DJ; Darabi S; Han IW; Evans DB; Yamada S; Demeure MJ; Becerra C; Celinski SA; Borazanci E; Tsai S; Kodera Y; Park JO; Bolton JS; Wang X; Kim SC; Von Hoff D; Goel A
    Gastroenterology; 2022 Nov; 163(5):1252-1266.e2. PubMed ID: 35850192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis.
    Deng T; Yuan Y; Zhang C; Zhang C; Yao W; Wang C; Liu R; Ba Y
    Cell Physiol Biochem; 2016; 39(5):1716-1722. PubMed ID: 27639768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Usefulness of exosome-encapsulated microRNA-451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcinoma.
    Takahasi K; Iinuma H; Wada K; Minezaki S; Kawamura S; Kainuma M; Ikeda Y; Shibuya M; Miura F; Sano K
    J Hepatobiliary Pancreat Sci; 2018 Feb; 25(2):155-161. PubMed ID: 29130611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma?
    Liu DSK; Mato Prado M; Giovannetti E; Jiao LR; Krell J; Frampton AE
    Expert Rev Mol Diagn; 2019 Jul; 19(7):553-558. PubMed ID: 31159604
    [No Abstract]   [Full Text] [Related]  

  • 30. Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma.
    Ghassem-Zadeh S; Gaida MM; Szanyi S; Acha-Orbea H; Frossard JL; Hinz U; Hackert T; Strobel O; Felix K
    J Transl Med; 2017 Jun; 15(1):126. PubMed ID: 28578701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
    Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.
    Gablo N. A; Procházka V; Hlavsa J; Kiss I; Srovnal J; Kala Z; Slabý O
    Klin Onkol; 2019; 32(Suppl 1):174-176. PubMed ID: 31064193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.
    Wang X; Li Y; Tian H; Qi J; Li M; Fu C; Wu F; Wang Y; Cheng D; Zhao W; Zhang C; Wang T; Rao J; Zhang W
    BMC Cancer; 2014 Aug; 14():578. PubMed ID: 25106741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma.
    Michael Traeger M; Rehkaemper J; Ullerich H; Steinestel K; Wardelmann E; Senninger N; Abdallah Dhayat S
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2419-2431. PubMed ID: 30244390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway.
    Yin Z; Ma T; Huang B; Lin L; Zhou Y; Yan J; Zou Y; Chen S
    J Exp Clin Cancer Res; 2019 Jul; 38(1):310. PubMed ID: 31307515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy.
    Yang KS; Im H; Hong S; Pergolini I; Del Castillo AF; Wang R; Clardy S; Huang CH; Pille C; Ferrone S; Yang R; Castro CM; Lee H; Del Castillo CF; Weissleder R
    Sci Transl Med; 2017 May; 9(391):. PubMed ID: 28539469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-released exosomal circular RNA PDE8A promotes invasive growth via the miR-338/MACC1/MET pathway in pancreatic cancer.
    Li Z; Yanfang W; Li J; Jiang P; Peng T; Chen K; Zhao X; Zhang Y; Zhen P; Zhu J; Li X
    Cancer Lett; 2018 Sep; 432():237-250. PubMed ID: 29709702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
    Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
    JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of platelet-lymphocyte ratio and CA 19-9 in differentiating benign from malignant head masses in patients with chronic pancreatitis.
    Kakkat S; Rajan R; Sindhu RS; Natesh B; Raviram S
    Indian J Gastroenterol; 2017 Jul; 36(4):263-267. PubMed ID: 28916969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-Specific miRNA Signatures in Combination with CA19-9 for Liquid Biopsy-Based Detection of PDAC.
    Kim MW; Koh H; Kim JY; Lee S; Lee H; Kim Y; Hwang HK; Kim SI
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.